NorthRock Partners’s VanEck Biotech ETF BBH Stock Holding History

NorthRock Partners’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-756	Closed	-$119K	–	695
2025 Q1	$119K	Hold	756	–	–	﹤0.01%	616
2024 Q4	$119K	Sell	756 -75	-9%	-$12.6K	﹤0.01%	602
2024 Q3	$147K	Sell	831 -305	-27%	-$54.1K	﹤0.01%	627
2024 Q2	$191K	Buy	1,136 +505	+80%	+$82.6K	0.01%	579
2024 Q1	$105K	Hold	631	–	–	﹤0.01%	626
2023 Q4	$104K	Buy	+631	New	+$97.1K	﹤0.01%	588

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NorthRock Partners's BBH Position: Q2 2025 in Review

NorthRock Partners sold out of VanEck Biotech ETF (BBH) in Q2 2025, closing a stake of 756 shares — an estimated $119K sold.

NorthRock Partners first reported a position in BBH in Q4 2023 and held it in 6 quarters. The position peaked at $191K in Q2 2024. 98 funds tracked by Wall St. Rank hold BBH as of Q2 2025.

NorthRock Partners reported no remaining VanEck Biotech ETF position as of Q2 2025 after selling out during the quarter.
NorthRock Partners sold 756 VanEck Biotech ETF shares in Q2 2025, an estimated $119K.
NorthRock Partners first reported a position in VanEck Biotech ETF in Q4 2023 and held it in 6 quarters.
NorthRock Partners's VanEck Biotech ETF position peaked at $191K in Q2 2024.
98 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2025.

Based on NorthRock Partners's 13F filing for Q2 2025, filed 25 Jul 2025.